OncoMatch/Clinical Trials/NCT05376878
An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis
Is NCT05376878 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including Trastuzumab and Trastuzumab Deruxtecan for anatomic stage iv breast cancer ajcc v8.
Treatment: Positron Emission Tomography · Trastuzumab · Trastuzumab Deruxtecan — This clinical trial examines an investigational scan (64Cu-DOTA-trastuzumab positron emission tomography \[PET\]/magnetic resonance imaging \[MRI\]) in imaging patients with HER2+ breast cancer that has spread to the brain (brain metastasis). Diagnostic procedures, such as 64Cu-DOTA-trastuzumab PET/MRI, may help find HER2+ breast cancer that has spread to the brain and determine whether cancer in the brain takes up trastuzumab, which may predict for response to trastuzumab deruxtecan (the standard of care chemotherapy).
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Tumor Agnostic
Biomarker criteria
Required: HER2 (ERBB2) overexpression (HER2 positive (per ASCO/CAP guidelines))
HER2 positive breast cancer (American Society of Clinical Oncology [ASCO] College of American Pathologist [CAP] guidelines)
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
ANC > 1.5 x 10^9/L; Platelets > 100 x 10^9/L; Hemoglobin > 9 g/dL
Kidney function
Creatinine clearance > 30 ml/min (by Cockcroft-Gault formula)
Liver function
Total bilirubin < 3 x ULN; AST and ALT < 5 x ULN
Cardiac function
Left ventricular ejection fraction (LVEF) > 50%
Left ventricular ejection fraction (LVEF) > 50%; ANC > 1.5 x 10^9/L; Platelets > 100 x 10^9/L; Hemoglobin > 9 g/dL; Total (T.) bilirubin < 3 x upper limit of normal (ULN); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 5 x ULN; Creatinine clearance > 30 ml/min (by Cockcroft-Gault formula); Activated partial thromboplastin time (aPTT) < 1.5 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Medical Center · Duarte, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify